Alaunos Therapeutics, Inc. (TCRT) Stock Analysis

Company Overview

Alaunos Therapeutics, Inc. (TCRT) is capitalised at $4.14M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1.

The 52-week range on file runs from $1.55 to $4.59. TCRT last closed at $1.63 on September 4, 2026. That is −$0.02 (−1.21%) against the previous close. The latest close sits 5.16% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.00K. Against the prior fiscal year total of $10.00K, that is a change of −50.00%. The same year closed with a net loss of $4.18M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.72.

Across the 4 fiscal years on file, revenue moves from $2.92M in 2022 to $5.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.58. Measured against sales, the shares trade at 1,380.33 times revenue. On price-to-sales that is 90.4 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is −0.97. Annualized volatility over the trailing 10 years is 105.8%. The trailing one-year price return is −24.54%. Across 10 years the annualized return works out at −45.77%.

Growth & Income

The record shows no dividend for TCRT.

2026 is still running; the price is −49.54% year to date. Across the complete calendar years on file, 2019 returned +152.41% and 2023 returned −89.23%. Of the 9 complete calendar years on file, 2 finished higher.